Back grey_arrow_rt.gif
 
 
Patient with severe influenza A (H1N1)
improves after treatment with intravenous Relenza: report
 
 
  by Anna Bratulic
September 04, 2009 firstword.com
 
Physicians treating a woman with severe influenza A (H1N1) infection who was not responding to standard therapies stated that the patient's condition improved after being treated with an unlicensed intravenous formulation of GlaxoSmithKline's Relenza (zanamivir), according to a case study documented in The Lancet. The physicians wrote that "although this is a single case report and direct cause and effect cannot be confirmed, the improvement in clinical status following intravenous Relenza encourages prompt further investigation."
 
Prior to receiving intravenous Relenza, the condition of the patient, who had recently undergone chemotherapy for Hodgkin's disease, had deteriorated to the point of requiring ventilation. The patient did not respond to treatment with Roche's Tamiflu (oseltamivir) given orally twice daily, or the inhaled formulation of Relenza. However, after being administered the intravenous version of GlaxoSmithKline's product in combination with high-dose corticosteroids, the patient's condition improved within 48 hours and she recovered with no side effects, the doctors said.
 
Reference Articles
 
Intravenous Relenza saves swine flu woman - doctors - (Forbes)
 
New method may fight drug-resistant swine flu - (MSNBC)
 
Swine flu woman saved by Relenza drip - (The Guardian)
 
H1N1 pneumonitis treated with intravenous zanamivir - (The Lancet)
 
Antiviral drug saves UK swine flu victim - (The Sydney Morning Herald)
 
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org